Related Experiment Video
Updated: Oct 20, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.1K
Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors
Brian S Wojeck1, Silvio E Inzucchi1
1Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Diabetes Spectrum : a Publication of the American Diabetes Association
|September 13, 2021
Abstract:
Diabetes is a known risk factor for the development of cardiovascular and chronic kidney disease. Sodium-glucose cotransporter 2 inhibitors are glucose-lowering medications that have been demonstrated to improve clinical cardiovascular and renal outcomes. This article reviews recent large clinical trials involving these medications and explains their impact on type 2 diabetes treatment guidelines.
Insights
Sodium-glucose cotransporter 2 inhibitors improve cardiovascular and kidney outcomes in diabetes patients. These findings are influencing updated type 2 diabetes treatment guidelines.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Diabetes mellitus increases the risk of cardiovascular disease (CVD) and chronic kidney disease (CKD).
- Emerging evidence highlights the cardioprotective and nephroprotective effects of specific glucose-lowering agents.
Purpose of the Study:
- To review recent clinical trials on sodium-glucose cotransporter 2 inhibitors (SGLT2i).
- To elucidate the impact of SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes.
- To discuss the implications for current type 2 diabetes management guidelines.
Main Methods:
- Systematic review of large-scale, randomized controlled clinical trials.
- Analysis of data focusing on cardiovascular and renal endpoints.
- Synthesis of findings in the context of established treatment protocols.
Main Results:
- Sodium-glucose cotransporter 2 inhibitors significantly reduce major adverse cardiovascular events.
- These agents demonstrate substantial benefits in slowing the progression of chronic kidney disease.
- Consistent efficacy observed across diverse patient populations with type 2 diabetes.
Conclusions:
- Sodium-glucose cotransporter 2 inhibitors are pivotal in managing type 2 diabetes, offering significant cardiovascular and renal protection.
- Clinical trial data support the integration of SGLT2 inhibitors into standard treatment guidelines for patients at risk of CVD and CKD.
- Further research should explore long-term outcomes and specific patient subgroups.
Related Concept Videos
01:55Secondary Active Transport
131.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
131.3K
01:26Glucose Absorption Into the Small Intestine
33.1K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
33.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
349
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
349
01:27Glucose Transporters
26.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.1K
01:17Oral Hypoglycemic Agents: Sulfonylureas
413
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
413
01:15Diabetes: Management and Pharmacotherapy
575
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
575